Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
Open Access
- 24 December 2020
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (3), 233-241
- https://doi.org/10.1136/jnnp-2020-323999
Abstract
Introduction The management of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) remains challenging in view of the paucity of data and evidence-based treatment recommendations are missing. Methods In this single-centre, non-randomised, prospective open-label study, we evaluated and compared the efficacy of oral and parenteral treatments for SUNCT and SUNA in a real-world setting. Additionally, single-arm meta-analyses of the available reports of SUNCT and SUNA treatments were conducted. Results The study cohort comprised 161 patients. Most patients responded to lamotrigine (56%), followed by oxcarbazepine (46%), duloxetine (30%), carbamazepine (26%), topiramate (25%), pregabalin and gabapentin (10%). Mexiletine and lacosamide were effective in a meaningful proportion of patients but poorly tolerated. Intravenous lidocaine given for 7–10 days led to improvement in 90% of patients, whereas only 27% of patients responded to a greater occipital nerve block. No statistically significant differences in responders were observed between SUNCT and SUNA. In the meta-analysis of the pooled data, topiramate was found to be significantly more effective in SUNCT than SUNA patients. However, a higher proportion of SUNA than SUNCT was considered refractory to medications at the time of the topiramate trial, possibly explaining this isolated difference. Conclusions We propose a treatment algorithm for SUNCT and SUNA for clinical practice. The response to sodium channel blockers indicates a therapeutic overlap with trigeminal neuralgia, suggesting that sodium channels dysfunction may be a key pathophysiological hallmark in these disorders. Furthermore, the therapeutic similarities between SUNCT and SUNA further support the hypothesis that these conditions are variants of the same disorder.Keywords
This publication has 37 references indexed in Scilit:
- Bedside cognitive assessments and falls risk in Parkinson’s diseaseNeurological Sciences, 2011
- Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2011
- SUNCT Syndrome Successfully Treated with the Combination of Oxcarbazepine and GabapentinPain Medicine, 2009
- Efficacy and Safety of Lacosamide in Diabetic Neuropathic PainThe Clinical Journal of Pain, 2009
- Efficacy of Gabapentin in the Treatment of SUNCT SyndromeCephalalgia, 2008
- Short-Lasting Unilateral Neuralgiform Headache Attacks with Conjunctival Injection and TearingCephalalgia, 2007
- SUNCT Syndrome With Dramatic Response To OxcarbazepineCephalalgia, 2006
- Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: A double-blind placebo-controlled studyPain, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High‐Voltage‐Activated Calcium CurrentsEpilepsia, 1995